title: Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia.
abstract: In acute myelogenous leukemia, early treatment is usually attempted with the so-called 3+7 regimen, employing daunorubicin (DNR) or idarubicin (IDR) for 3 consecutive days. In acute lymphoblastic leukemia (ALL), the role of agreement regarding ANT dosage and schedule, preferable compound, and indications for remission induction and consolidation treatment phases. Here we review the role of these drugs in adult ALL. The results indicate that ANTs may offer the best survival chance when used at full dosage during induction and early consolidation treatment. IDR may be a better choice that DNR or doxorubicin, and CD10+ t(9;22)/bcr- ALL may have an excellent prognosis following an early dose-intensive ANT consolidation program.
authors.affiliation: Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italia.
authors.forename: R
authors.initials: R
authors.lastname: Bassan
authors.forename: T
authors.initials: T
authors.lastname: Lerede
authors.forename: A
authors.initials: A
authors.lastname: Rambaldi
authors.forename: T
authors.initials: T
authors.lastname: Barbui
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000145:classification / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D015255:Idarubicin; D003630:Daunorubicin